OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Formulation business grew by 15 per cent in the quarter
The aim is to create new genomics solutions that could combat cancer and advance market access
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Deal signed with AOP Orphan for US commercial rights
The drug is indicated for mild and transient episodes of heart block
Subscribe To Our Newsletter & Stay Updated
